Provided by Tiger Trade Technology Pte. Ltd.

Sarepta Therapeutics

18.21
+0.71004.06%
Post-market: 18.18-0.0300-0.16%18:13 EDT
Volume:3.52M
Turnover:63.35M
Market Cap:1.92B
PE:-13.84
High:18.28
Open:17.28
Low:17.20
Close:17.50
52wk High:25.32
52wk Low:14.68
Shares:105.57M
Float Shares:99.05M
Volume Ratio:1.33
T/O Rate:3.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3161
EPS(LYR):-7.1300
ROE:-9.48%
ROA:-1.13%
PB:1.26
PE(LYR):-2.55

Loading ...

Shares of Some Drug Developers Fall Premarket After Novartis Late-Stage Muscle Disorder Trial Fails

THOMSON REUTERS
·
Sep 08

Novartis Twin Drug Setbacks Pile Pressure on Pipeline, CEO

Reuters
·
Sep 08

J.P. Morgan Remains a Hold on Sarepta Therapeutics (SRPT)

TIPRANKS
·
Sep 02

Sarepta to Present at Morgan Stanley Global Healthcare Conference Fireside Chat

Reuters
·
Sep 01

Sarepta Therapeutics (SRPT) Could Be 30% Undervalued After Elevidys Progress Hopes

Simply Wall St.
·
Aug 28

Sarepta Therapeutics, Inc. : JP Morgan Raises Target Price to $23 from $19

THOMSON REUTERS
·
Aug 27

Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial

Dow Jones
·
Aug 24

Trump Picks White House Adviser Heidi Overton to Run FDA, Source Says

Reuters
·
Aug 19

Evercore ISI Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)

TIPRANKS
·
Aug 10

Regenxbio Seen on Track for Duchenne Approval as Data Strengthens, RBC Says

MT Newswires Live
·
Aug 08

Sarepta Therapeutics (SRPT) Stock Rally Hinges On Profit Progress And Revenue Drop

Simply Wall St.
·
Aug 07

Sarepta Faces Competitive Pressures Despite Pipeline Updates, RBC Says

MT Newswires Live
·
Aug 07

Oppenheimer Adjusts PT on Sarepta Therapeutics to $35 From $37, Maintains Outperform Rating

MT Newswires Live
·
Aug 06

Analysts Offer Insights on Healthcare Companies: Agilon Health (AGL), CVS Health (CVS) and Sarepta Therapeutics (SRPT)

TIPRANKS
·
Aug 06

Wedbush Keeps Their Buy Rating on Sarepta Therapeutics (SRPT)

TIPRANKS
·
Aug 06

Sarepta Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Sarepta reports Q2 adjusted EPS 64c, consensus 49c

TIPRANKS
·
Aug 06

Sarepta Q2 Results Beat Expectations Despite Lower Sales Stemming from Elevidys Relabel, Unmet Roche Milestone

Reuters
·
Aug 06

Sarepta Therapeutics Q2 Adj. EPS $0.64 Beats $0.26 Estimate, Sales $401.300M Beat $364.343M Estimate

Benzinga Earnings
·
Aug 06

Sarepta Q2 FY26 Net Income Turns to USD 4.89 Million Loss; Revenue Drops 34% to USD 401.25 Million

Reuters
·
Aug 06